Comments
Drug major Lupin today said it has received final approval from the United States Food and Drug Administration (USFDA) to market Hydrocortisone Butyrate lotion, used for the treatment of mild atopic dermatitis in patients 3 months of age and older, in the US market.
The approved product is a generic version of PreCision Dermatology, Inc.’s (PreCision) Locoid Lotion, 0.1 per cent, Lupin said in a BSE filing. According to IQVIA MAT data of April 2018, Lupin said the product had annual sales of around $13.8 million in the US. Shares of Lupin were trading 0.77 per cent higher at Rs 876.50 apiece on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.